Core Viewpoint - Yuaneng Bio has officially launched its Series B financing and is actively preparing for its listing on the Sci-Tech Innovation Board, focusing on the automation of low-temperature storage technology for nearly eight years [1][5]. Group 1: Company Development and Innovations - The company has applied for over 600 domestic and international patents, with more than 500 granted as of December 2024 [1]. - Yuaneng Bio aims to innovate and industrialize low-temperature storage technology, moving from laboratory applications to broader industrial use, driven by policy, capital, and entrepreneurial efforts [1][5]. - The company has invested nearly 800 million yuan in the development of advanced automated low-temperature storage equipment [2]. Group 2: Product and Market Strategy - Yuaneng Bio has developed a series of automated deep low-temperature biological sample storage devices, achieving a breakthrough from 0 to 1 in research and development [3]. - The company is currently in the small-batch manufacturing phase, focusing on standardizing and modularizing its products to reduce production costs [3]. - Yuaneng Bio has successfully implemented its automated equipment in various projects, including those with the Chinese CDC and several hospitals [2]. Group 3: Future Outlook and Expansion - The company plans to enhance its global presence while deepening its domestic market engagement, with a focus on expanding its customer base internationally [3]. - Yuaneng Bio's Orcella Instruments brand won the "Outstanding New Product Award" at the ISBER awards in Canada, highlighting its international recognition [3]. - The company is set to complete a smart manufacturing base in Shanghai in 2024, covering nearly 10,000 square meters, to support its production capabilities [5].